NVCR
NovoCure Ltd

7,390
Mkt Cap
$1.28B
Volume
1.99M
52W High
$34.13
52W Low
$10.70
PE Ratio
-7.41
NVCR Fundamentals
Price
$11.95
Prev Close
$11.46
Open
$11.40
50D MA
$12.90
Beta
1.24
Avg. Volume
1.64M
EPS (Annual)
-$1.56
P/B
3.92
Rev/Employee
$406,733.87
Loading...
Loading...
News
all
press releases
Los Angeles Capital Management LLC Cuts Stake in NovoCure Limited $NVCR
Los Angeles Capital Management LLC lessened its holdings in shares of NovoCure Limited (NASDAQ:NVCR - Free Report) by 40.6% in the 2nd quarter, according to the company in its most recent 13F filing...
MarketBeat·6d ago
News Placeholder
More News
News Placeholder
Campbell & CO Investment Adviser LLC Takes $715,000 Position in NovoCure Limited $NVCR
Campbell & CO Investment Adviser LLC purchased a new position in NovoCure Limited (NASDAQ:NVCR - Free Report) during the second quarter, according to its most recent disclosure with the Securities...
MarketBeat·6d ago
News Placeholder
Novocure to Participate in 2025 Jefferies Global Healthcare Conference
Novocure (NASDAQ: NVCR) announced today that management will participate in the Jefferies Global Healthcare Conference in London on Wednesday, November 19, 2025. Ashley Cordova, Chief Executive...
Business Wire·10d ago
News Placeholder
Connor Clark & Lunn Investment Management Ltd. Has $10.87 Million Position in NovoCure Limited $NVCR
Connor Clark & Lunn Investment Management Ltd. grew its position in NovoCure Limited (NASDAQ:NVCR - Free Report) by 14.2% in the 2nd quarter, according to its most recent filing with the Securities...
MarketBeat·10d ago
News Placeholder
NovoCure (NASDAQ:NVCR) Sets New 52-Week Low - What's Next?
NovoCure (NASDAQ:NVCR) Reaches New 52-Week Low - What's Next...
MarketBeat·14d ago
News Placeholder
Compared to Estimates, NovoCure (NVCR) Q3 Earnings: A Look at Key Metrics
The headline numbers for NovoCure (NVCR) give insight into how the company performed in the quarter ended September 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Zacks·23d ago
News Placeholder
NovoCure (NVCR) Reports Q3 Loss, Tops Revenue Estimates
NovoCure (NVCR) delivered earnings and revenue surprises of +21.43% and +5.76%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·23d ago
News Placeholder
Novocure Reports Third Quarter 2025 Financial Results
Novocure (NASDAQ: NVCR) today reported financial results for the third quarter that ended September 30, 2025. Novocure is a global oncology company working to extend survival in some of the most...
Business Wire·23d ago
News Placeholder
Novocure to Present New Research for Tumor Treating Fields (TTFields) Therapy at European Association of Neuro-Oncology (EANO) Meeting and the European Society for Medical Oncology (ESMO) Congress
Novocure (NASDAQ: NVCR) announced today that it will present data at two upcoming oncology congresses, the 2025 European Association of Neuro-Oncology (EANO) Meeting, being held October 16-19 in...
Business Wire·1mo ago
News Placeholder
NVCR Stock Slips Despite PMA Application to Treat Pancreatic Cancer
NovoCure submits a PMA to the FDA for TTFields therapy in pancreatic cancer, aiming to expand its oncology reach.
Zacks·3mo ago

Latest NVCR News

View

Advertisement|Remove ads.

Advertisement|Remove ads.